The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Eisai; Exelixis; Janssen Oncology; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Eisai; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Aniko Szabo
No Relationships to Disclose
 
Kathryn Bylow
No Relationships to Disclose
 
Ariel Nelson
No Relationships to Disclose
 
Peter Langenstroer
No Relationships to Disclose
 
Scott Johnson
No Relationships to Disclose
 
Arjun Sivaraman
No Relationships to Disclose
 
Kenneth Jacobsohn
No Relationships to Disclose
 
Chunkit Fung
Consulting or Advisory Role - Exelixis; Novartis; Novartis
Research Funding - Astellas Pharma (Inst)
 
Sindhuja Kadambi
No Relationships to Disclose
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai
 
Melissa Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Astellas Pharma; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Robert Alter
No Relationships to Disclose
 
Asit Paul
No Relationships to Disclose
 
Brendan Guercio
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Oncocyte
Travel, Accommodations, Expenses - AVEO; DAVA Oncology; EMD Serono; Gilead Sciences; Natera; Seagen
(OPTIONAL) Uncompensated Relationships - Flare Therapeutics
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Roche (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly